Shares Broad USD Investment Grade Corporate Bond ETF (USIG) オプション

https://x.com/Beppels1/status/1890449070923141202

Both are happening.

Nasdaq then buyout.

His intention is to suggest with certainty that we are headed for a reverse split and not a buyout.

GOOD CALL

GLYC BELL BUY INTO VOLUME AND BIG GAPPER

btw FP still owes all those investors he robbed

30-50 days

Cawww caww

Oh yea 🦆🦆 is so 2022 we got a new scam

Hey Charles, what happened 🦆 🦆 go

LIONS GROUP CBD EVANS CYBER ZEN

Jzzi CBD HONEY GREG EVANS 55 UP

You don't have the energy, except for pompous reasons.

Got it.

My post keep getting removed, obviously making one of the Trump babies mad. 

I hope we all benefit from this great beer co and see the awesome results in the report coming out soon, The bashers or the fool force is in for a big wake up call, northbound we go!

Warning‼️
All Shorties‼️

Last One Out is a Rotten Egg‼️

Yeah I feel the same way recently. Both the OTC and crypto are pissing me off. I keep buying more and more crypto on many of these dips. It's really boom or bust for me.

The main trial didn't fail dude, one primary endpoint failed, which is not the same.

That endpoint is in the process of being removed by the FDA which you likely knew already.

Why are you lying?

https://x.com/maxinvestor89/status/1891752794396229705?s=46&t=He3ILIizDMal7FFXIIgFjw

Correction, on the house bill 1396, copied from redit,

https://www.reddit.com/r/WallStreetbetsELITE/comments/1irl3m7/how_hr1396_could_impact_the_stock_market_generic/

can't find on google, it's in the ways and means committee
I think

Good morning, Larry, the cold is returning again.

mailconversation with IR
read the reply
- Appreciate your patience as we've worked to get you answers to some of these questions. Management is not in a position to provide an update on the commercial strategy with firm targets, timelines, etc. as that would constitute a material upda

There is ZERO dilution here. No warrants no overhead supply. 

Happy Birthday, B2B!

Interesting update on the biosimilar candidate FYB206 with Merck's Keytruda:

"Regulatory developments in the U.S. indicate that the framework conditions for biosimilars continue to improve. The FDA has confirmed that extensive analytical data, together with the ongoing phase I trial,

*Super* " Happy BirthDay, back2basics " ..!!

Shortie is DOOMED‼️

Rude Awaking‼️

MOASS Alert 🚨 ‼️

Ring the Bell 🛎️ ‼️